# OnCo record syncromune (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/syncromune/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "syncromune" ;
  schema:name "Syncromune"@en ;
  schema:alternateName "Syncromune, Inc."@en ;
  schema:description "Syncromune's treatment, SYNC-T, freezes and breaks down a small part of one tumour and then infuses a mix of immune-stimulating drugs directly into it, aiming to train the immune system to attack cancer throughout the body. It is in a phase 2 trial for advanced prostate cancer that no longer responds to hormone treatment."@en ;
  schema:url <https://onco.cc/companies/syncromune/>, <https://syncromune.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://syncromune.com/>, <https://syncromune.com/science/>, <https://syncromune.com/2026/10/27/syncromune-reports-long-term-data-from-phase-1-study-in-metastatic-prostate-cancer-with-investigational-sync-t-therapy-sv-102/>, <https://clinicaltrials.gov/study/NCT06533644> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/in-situ-vaccination/>, <https://onco.cc/technologies/cryoablation-systems/> ;
  onco:trials <https://onco.cc/trials/nct06533644/> .